Qure.ai

Qure.ai positions itself as the world's most widely adopted healthcare AI platform, deployed across a large global network of sites.

Qure.ai's qER stroke/TBI AI cuts head CT read-and-diagnose time from roughly an hour to a couple of minutes, accelerating time-critical treatment decisions.

Qure.ai's solutions are positioned as WHO-evaluated tools that help clinicians make quick, accurate diagnosis and treatment decisions, alongside a large base of FDA-cleared indications.

Qure.ai's lung nodule pathway platform supports radiologists, pulmonologists and emergency physicians who read and act on chest imaging.

Qure.ai onboards its lung cancer detection, measurement and management suite onto hospital and health-system imaging workflows via partner networks such as Microsoft's Precision Imaging Network.

Qure.ai's chest X-ray AI tool qXR is used by government-run tuberculosis screening programs, with AI tools validated and recommended by ICMR deployed to screen presumptive TB cases in India.

Qure.ai reaches hospitals by embedding its AI directly into imaging hardware, integrating with X-ray and CT scanners across 85+ countries.

Qure.ai's AI portfolio is built to plug directly into radiology PACS/RIS workflows already used by hospitals and diagnostic centers.

Qure.ai partners directly with imaging device makers such as Fujifilm to ship AI-augmented X-ray solutions, including portable/mobile units for remote regions.

Qure.ai runs and publishes clinical validation studies for its algorithms (e.g. chest X-ray and head CT models) to support regulatory clearances and clinical adoption.

Qure.ai develops new AI products aimed at extending its reach beyond radiologists, e.g. a voice-based clinical co-pilot for frontline health workers in low- and middle-income countries.

Qure.ai holds a portfolio of patents and a large body of peer-reviewed publications and abstracts backing its AI algorithms.

Qure.ai has accumulated a wide base of FDA-cleared indications across its imaging AI product line.

Qure.ai's chest X-ray algorithm was trained on a large-scale proprietary dataset of over a million X-rays with corresponding radiology reports, underpinning its diagnostic accuracy claims.

AstraZeneca and Qure.ai jointly ran AI-enabled chest X-ray screening across more than 20 countries as part of AstraZeneca's commitment to the World Economic Forum's EDISON Alliance, reaching a 5 million-screening milestone.

Medtronic India partnered with Qure.ai to integrate AI stroke-triage tools into a hub-and-spoke network of stroke centers, combining Medtronic's neurosciences leadership with Qure's AI.

Qure.ai partnered with Microsoft to onboard its lung cancer detection and management suite onto Microsoft's Precision Imaging Network, to streamline deployment to US hospitals and health systems.

The large majority of Qure.ai's operating revenue comes from sale of its AI diagnostic tools and software to hospitals/health systems, which doubled to Rs 123 crore in FY24.

A smaller share of operating revenue comes from sale of healthcare products (the remainder of FY24 operating revenue beyond AI tools/software).

Employee benefit costs are Qure.ai's single largest expense line, making up nearly half of total costs and continuing to rise year over year.